Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234481 · ClinicalTrials.gov registry record · Phase 1
Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia
A Phase 1 study, sponsored by Exelixis.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00234481: Clinical Trial Phase 1 study, sponsored by Exelixis.
NCT00234481 is a Phase 1 study that was terminated before completion, run by Exelixis. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00234481, a Phase 1 study, was terminated before completion, sponsored by Exelixis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
The purpose of this study is to assess the safety and tolerability of different doses of XL844 when given orally to adults with recurrent or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Interventions
- DRUG XL844
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Why NCT00234481 stopped before completion
NCT00234481 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which XL844 is the first listed.
NCT00234481 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00234481 about?
NCT00234481 is a clinical study titled "Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia". The purpose of this study is to assess the safety and tolerability of different doses of XL844 when given orally to adults with recurrent or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
What is the current status of trial NCT00234481?
This trial is currently terminated. It is a Phase 1 study.
What interventions are being tested in trial NCT00234481?
The interventions under investigation include: XL844 (DRUG).
Who is sponsoring clinical trial NCT00234481?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.